Evidence map›Paper›PMID 37926336›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2024

Association Between Urinary Biomarkers and CKD in Extremely Low Gestational Age Neonates.

Sangeeta R Hingorani, Robert H Schmicker, Brian Halloran, Patrick Brophy, Patrick J Heagerty, Sandra Juul, Stuart L Goldstein, David Askenazi, PENUT Investigators

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01378273 (Preterm Erythropoietin Neuroprotection Trial), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01378273 phase3completednot on this map

Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)

TypeinterventionalSponsorUniversity of WashingtonRan2013 to 2020Enrolled941ConditionsExtreme PrematurityArmsEpo, Control
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Sangeeta R HingoraniDivisions of Nephrology, Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, Washington. Electronic address: sangeeta.hingorani@seattlechildrens.org.
Robert H SchmickerDepartment of Biostatistics, University of Washington, Seattle, Washington.
Brian HalloranDivision of Nephrology, Department of Pediatrics, University of Alabama at Birmingham, Children's of Alabama, Birmingham, Alabama.
Patrick BrophyDepartment of Pediatrics, University of Rochester School of Medicine, Rochester, New York.
Patrick J HeagertyDepartment of Biostatistics, University of Washington, Seattle, Washington.
Sandra JuulNeonatology, Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, Washington.
Stuart L GoldsteinDivision of Nephrology and Hypertension, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, Ohio.
David AskenaziDivision of Nephrology, Department of Pediatrics, University of Alabama at Birmingham, Children's of Alabama, Birmingham, Alabama.
PENUT Investigators
Children's of Alabama · USSeattle Children's Hospital · USUniversity of Washington · USCincinnati Children's Hospital Medical Center · USUniversity of Rochester · US

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Preterm Epo Neuroprotection Trial (PENUT Trial) CCCU01NS077953 · NINDS · UNIVERSITY OF WASHINGTON · PI JUUL, SANDRA E · 2013 to 2018
$10.7M
Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)R01DK103608 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI ASKENAZI, DAVID JOSEPH, GOLDSTEIN, STUART L · 2014 to 2019
$3.0M
Preterm Epo Neuroprotection Trial (PENUT Trial) DCCU01NS077955 · NINDS · UNIVERSITY OF WASHINGTON · PI HEAGERTY, PATRICK J · 2013 to 2018
$1.5M
NCATS NIH HHS UL1 TR002319NIDDK NIH HHS R01 DK103608NINDS NIH HHS U01 NS077953NINDS NIH HHS U01 NS077955
6 · The paper itself

Abstract

RATIONALE &

objectiveChildren born before 28 weeks' gestation are at increased risk of chronic kidney disease (CKD). Urine biomarkers may shed light on mechanistic pathways and improve the ability to forecast CKD. We evaluated whether urinary biomarkers in neonates of low gestational age (GA) are associated with a reduced estimated glomerular filtration rate (eGFR) over time. STUDY

designA cohort study of neonates with an exploratory case-control study of a subset of the cohort. SETTING &

participants327 neonates born at 24-27 weeks' gestation with 2-year eGFR data from the PENUT (Preterm Erythropoietin Neuroprotection Trial) and the REPaIReD (Recombinant Erythropoietin for Prevention of Infant Renal Disease) study. EXPOSURES: 11 urinary biomarkers measured at 27, 30, and 34 weeks' postmenstrual age for the primary cohort study and 10 additional biomarkers for the exploratory case-control study. OUTCOMES: eGFR<90mL/min/1.73m ANALYTICAL APPROACH: Linear mixed models to assess differences in biomarker values between neonates in whom CKD did and did not develop, accounting for multiple comparisons using Bonferroni-Holm correction in the cohort study only. Cohort analyses were adjusted for sex, GA, and body mass index. Cases were matched to controls on these variables in the case-control study.

resultsAfter adjusting for weeks of GA, urinary levels of α-glutathione-S-transferase (log difference, 0.27; 95% CI, 0.12-0.43), albumin (log difference, 0.13; 95% CI, 0.02-0.25), and cystatin C (log difference, 0.19; 95% CI, 0.04-0.34) were higher in those in whom CKD developed than in those in whom it did not. Urinary albumin and cystatin C levels did not remain significantly different after Bonferroni-Holm correction. In the exploratory case-control analysis, there were no differences in any biomarkers between cases and controls. LIMITATIONS: Early deaths and a high number of subjects without eGFR at 2 years corrected for GA.

conclusionsMeasurement of urinary biomarkers may assist in monitoring neonates who are at risk for CKD. Additional studies are needed to confirm these findings.

fundingGrants from government (National Institutes of Health).

trial registrationRegistered at ClinicalTrials.gov with study number NCT01378273. PLAIN-LANGUAGE SUMMARY: Approximately 15 million neonates worldwide are born prematurely, and 2 million are born before 28 weeks' gestation. Many of these children go on to experience chronic kidney disease. Urine biomarkers may allow for early recognition of those at risk for the development of kidney disease. In this study of more than 300 children born before 28 weeks' gestational age, we found higher mean urinary levels of α-glutathione-S-transferase at 27, 30, and 34 weeks in children whose estimated glomerular filtration rate was<90mL/min/1.73m

Indexed as

ErythropoietinRenal Insufficiency, ChronicAlbuminsBiomarkersCase-Control StudiesChildCohort StudiesCystatin CGestational AgeGlomerular Filtration RateGlutathioneHumansInfantInfant, NewbornTransferasesAlbuminsBiomarkersCystatin CErythropoietinGlutathioneTransferasesextreme prematurity, urinary biomarkers, chronic kidney disease

Identifiers

PMID37926336
PMCPMC10960703
OpenAlexW4388347597

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.